Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more
Cellid Co. Ltd (299660) - Net Assets
Latest net assets as of September 2025: ₩78.71 Billion KRW
Based on the latest financial reports, Cellid Co. Ltd (299660) has net assets worth ₩78.71 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩112.51 Billion) and total liabilities (₩33.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩78.71 Billion |
| % of Total Assets | 69.96% |
| Annual Growth Rate | 55.52% |
| 5-Year Change | 8.26% |
| 10-Year Change | N/A |
| Growth Volatility | 117.76 |
Cellid Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Cellid Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cellid Co. Ltd (2015–2024)
The table below shows the annual net assets of Cellid Co. Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩51.20 Billion | +26.44% |
| 2023-12-31 | ₩40.50 Billion | +80.47% |
| 2022-12-31 | ₩22.44 Billion | -42.11% |
| 2021-12-31 | ₩38.76 Billion | -18.05% |
| 2020-12-31 | ₩47.30 Billion | -7.86% |
| 2019-12-31 | ₩51.33 Billion | +280.35% |
| 2018-12-31 | ₩13.50 Billion | +344.15% |
| 2017-12-31 | ₩-5.53 Billion | -2585.53% |
| 2016-12-31 | ₩-205.83 Million | -121.41% |
| 2015-12-31 | ₩961.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellid Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6349995066000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.55 Billion | 20.61% |
| Other Components | ₩105.67 Billion | 206.38% |
| Total Equity | ₩51.20 Billion | 100.00% |
Cellid Co. Ltd Competitors by Market Cap
The table below lists competitors of Cellid Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Farmsco
KO:036580
|
$32.77 Million |
|
Berentzen Gruppe AG
XETRA:BEZ
|
$32.79 Million |
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
$32.79 Million |
|
Saraswanti Anugerah Makmur Pt
JK:SAMF
|
$32.79 Million |
|
Chuong Duong Corp
VN:CDC
|
$32.77 Million |
|
TEAM INC. DL-30
F:T9CA
|
$32.76 Million |
|
Coincheck Group N.V. Ordinary Shares
PINK:CNCK
|
$32.76 Million |
|
Zoomd Technologies Ltd
PINK:ZMDTF
|
$32.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellid Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,495,260,880 to 51,203,097,970, a change of 10,707,837,090 (26.4%).
- Net loss of 12,259,048,240 reduced equity.
- Share repurchases of 22,675,282,520 reduced equity.
- New share issuances of 22,675,282,520 increased equity.
- Other factors increased equity by 22,966,885,330.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.26 Billion | -23.94% |
| Share Repurchases | ₩22.68 Billion | -44.28% |
| Share Issuances | ₩22.68 Billion | +44.28% |
| Other Changes | ₩22.97 Billion | +44.85% |
| Total Change | ₩- | 26.44% |
Book Value vs Market Value Analysis
This analysis compares Cellid Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩-30.76 | ₩2685.00 | x |
| 2017-12-31 | ₩-762.50 | ₩2685.00 | x |
| 2018-12-31 | ₩1643.61 | ₩2685.00 | x |
| 2019-12-31 | ₩5358.73 | ₩2685.00 | x |
| 2020-12-31 | ₩4876.51 | ₩2685.00 | x |
| 2021-12-31 | ₩3479.32 | ₩2685.00 | x |
| 2022-12-31 | ₩2014.21 | ₩2685.00 | x |
| 2023-12-31 | ₩2644.08 | ₩2685.00 | x |
| 2024-12-31 | ₩2155.06 | ₩2685.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellid Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -294.33%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.49x
- Recent ROE (-23.94%) is above the historical average (-40.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -117.02% | -175.83% | 0.23x | 2.95x | ₩-1.22 Billion |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-1.75 Billion |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-4.86 Billion |
| 2018 | -83.63% | 0.00% | 0.00x | 1.05x | ₩-12.64 Billion |
| 2019 | -4.86% | 0.00% | 0.00x | 1.02x | ₩-7.63 Billion |
| 2020 | -8.72% | 0.00% | 0.00x | 1.04x | ₩-8.86 Billion |
| 2021 | -33.72% | -1437.76% | 0.02x | 1.50x | ₩-16.95 Billion |
| 2022 | -101.90% | -4763.45% | 0.01x | 2.04x | ₩-25.11 Billion |
| 2023 | -28.67% | 0.00% | 0.00x | 1.58x | ₩-15.66 Billion |
| 2024 | -23.94% | -294.33% | 0.05x | 1.49x | ₩-17.38 Billion |
Industry Comparison
This section compares Cellid Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellid Co. Ltd (299660) | ₩78.71 Billion | -117.02% | 0.43x | $32.77 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |